Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2010 Jul;28(7):1422-8.
doi: 10.1097/HJH.0b013e3283392673.

Urinary angiotensinogen is correlated with blood pressure in men (Bogalusa Heart Study)

Hiroyuki Kobori  1 , Maki Urushihara, Ji H Xu, Gerald S Berenson, Luis Gabriel Navar
Affiliations
Comparative Study

Urinary angiotensinogen is correlated with blood pressure in men (Bogalusa Heart Study)

Hiroyuki Kobori et al. J Hypertens. 2010 Jul.

Abstract

Background: The Bogalusa Heart Study is a long-term study on cardiovascular disease and has followed a biracial (black/white) population from childhood. Risk factor data pertaining to many patients have been collected over 35 years, and the time course of hypertension has been documented by repeated examinations and measurements. Considerable sex and racial differences have been found to be related to cardiovascular disease. Urinary angiotensinogen (UAGT) is a novel biomarker for the intrarenal activity of the renin-angiotensin system in hypertension and kidney disease. We aimed to determine the relationship of UAGT with traditional cardiovascular disease risk factors in asymptomatic young adults in this biracial population.

Method: We recruited 251 individuals and collected a single random spot urine sample from each one. Because UAGT is significantly increased in diabetic patients and the use of antihypertensive drugs affects UAGT levels, we excluded patients who had diabetes, who were receiving antihypertensive treatment, or both. Consequently, 190 participants were included for this analysis.

Results: UAGT levels did not differ with race or sex, but were significantly correlated with SBP (r = +0.23, P = 0.0015) and DBP (r = +0.24, P = 0.0012). Moreover, high correlations were shown in men, especially in black men (SBP, r = +0.85, P = 0.0005 and DBP, r = +0.72, P = 0.0079). Thus, UAGT is correlated with blood pressure in men, even when they do not show overt proteinuria or albuminuria.

Conclusion: The biomarker, UAGT, may facilitate the identification of individuals that are at increased risk for the development of hypertension and early asymptomatic renal disease.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Fig. 1
Fig. 1
(a and b) Single regression analyses for urinary angiotensinogen–creatinine ratio levels. UAGT/UCre levels are not correlated with age, height (r = −0.03, P = 0.6481), body weight (r = +0.00, P = 0.9745), BMI, serum sodium levels, serum creatinine levels (r = −0.11, P = 0.131), serum cystatin C levels, or fractional excretion of sodium. However, UAGT/UCre levels are significantly and positively correlated with SBP (a; r = +0.23, P = 0.0015), DBP (b; r = +0.24, P = 0.0012), urinary sodium–creatinine ratio (r = +0.16, P = 0.0342), urinary albumin–creatinine ratio (r = +0.39, P <0.0001), and urinary protein–creatinine ratio (r = +0.47, P <0.0001). (c) Multiple regression analyses for UAGT/UCre levels. Only three parameters (DBP, urinary sodium–creatinine ratio, and urinary protein–creatinine ratio) can account for almost 30% of variation of UAGT/UCre levels (r = 0.54, R2 = 0.29, P <0.0001). (d–f) Relationship of UAGT/UCre levels with blood pressure in populations. UAGT/UCre levels were not different among race or sex (d). However, as described in this figure, UAGT/UCre levels were significantly correlated with SBP and DBP. Moreover, high correlations were shown in men, especially in black men in SBP (e; r = +0.85, P = 0.0005) and DBP (f; r = +0.72, P = 0.0079). UAGT/UCre; urinary angiotensinogen–creatinine ratio (in μg/g).
Fig. 2
Fig. 2
Perspectives based on the findings in this observational study. SNP, single-nucleotide polymorphisms
See this image and copyright information in PMC

References

    1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206–1252. - PubMed
    1. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827–838. - PubMed
    1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) JAMA. 2002;288:2981–2997. - PubMed
    1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-llt) JAMA. 2002;288:2998–3007. - PubMed
    1. Heerspink HJ, Ninomiya T, Zoungas S, de Zeeuw D, Grobbee DE, Jardine MJ, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2009;373:1009–1015. - PMC - PubMed

Publication types

MeSH terms

Substances